Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 162   

Articles published

BMY 65.06 -0.26 (-0.40%)
price chart
Earnings Buzz: Pfizer Inc (PFE), Merck & Co Inc (MRK), Bristol-Myers Squibb Co ...
Earnings season continues in full swing this week as pharmaceutical giants Pfizer Inc., Merck & Co. Inc. and Bristol-Myers Squibb Co. are among 40 Standard & Poor's 500 companies reporting quarterly results Tuesday. Of the S&P 500 companies that have ...
Bristol-Myers Squibb Announces Cash Tender Offer For Up to $400 Million ...  Stockhouse
Pfizer, Merck and Bristol-Myers Squibb Report Solid Results  Wall Street Journal
MMM Now #42 Largest Company, Surpassing Bristol-Myers Squibb
Market capitalization is an important data point for investors to keep an eye on, for various reasons. The most basic reason is that it gives a true comparison of the value attributed by the stock market to a given company's stock. Many beginning ...
Bristol-Myers Squibb Company (BMY) Option Bulls Buoyed By Deal-Making  Schaeffers Research (blog)
CheckMate -057, a Pivotal Phase III Opdivo (nivolumab) Lung Cancer Trial ...  MarketWatch
Bristol-Myers Squibb Prices �1.15 Billion of Senior Notes
NEW YORK, Apr 29, 2015 (BUSINESS WIRE) -- Bristol-Myers Squibb Company BMY, -0.39% announced today that it has agreed to sell �1.15 billion of senior unsecured notes: �575,000,000 in aggregate principal amount of 1.000% notes due 2025 and ...
Fitch Rates Bristol-Myers Squibb's Euro Bond Issuance 'A-'  Reuters
Bristol-Myers Squibb Co (BMY) Updates FY15 Earnings Guidance  The Legacy
Bristol-Myers Squibb Company (BMY) Dip Doesn't Deter Option Bulls
Since hitting a 14-year high $69.20 on March 20, Bristol-Myers Squibb Co (NYSE:BMY) has dropped 7%, recently consolidating above its 60-day moving average.
Bristol-Myers Squibb Receives Average Rating of "Hold" from ...  Dakota Financial News
Morningstar Issues AA- Credit Rating to Bristol-Myers Squibb (BMY)  Mideast Time
Bristol-Myers Squibb Co sNDA For New Indication Of Opdivo Cleared For FDA ...
Bristol-Myers Squibb Co (NYSE:BMY) received the US Food and Drug Administration's (FDA) approval on Wednesday to review its supplemental New Drug Application (sNDA) for Opdivo (nivolumab).
Market Update (NYSE:BMY): U.S. Food and Drug Administration Accepts ...  Jutia Group
U.S. Food and Drug Administration Accepts Supplemental Biologics License ...  Business Wire (press release)
How Bristol-Myers Squibb (BMY) Makes its Money
As drug makers go, Bristol-Myers Squibb Co. (BMY) is acquisitive. Just in the last three years it's spent billions purchasing companies such as Amylin Pharmaceuticals and Flexus Biosciences, Inc., adding several valuable patents to an already extensive ...
General Report on Bristol-Myers Squibb Company (NYSE:BMY)  Street Report
High Outflow of Money Witnessed in Bristol-Myers Squibb Company  Trade Journo
Is Bristol-Myers Squibb. Co. About to Fall Apart?
The somewhat baffling part of Bristol's surge, though, is that its underlying business has been struggling due to multiple top-selling drugs losing exclusivity and the company's decision to exit its lucrative diabetes alliance with AstraZeneca (NYSE ...
UPDATE: Bristol-Myers Squibb (BMY) Likely to Beat Consensus FY15-16 ...  StreetInsider.com
Bristol-Myers Squibb Co (BMY) Rumored To Be Interested In Celgene Corporation  Bidness ETC
Will Schizophrenia and Bipolar Patients Trust Generic Abilify?
Bristol-Myers Squibb Co. (NYSE: BMY). Otsuka's sales partner, generated some $554 million in global sales of Abilify in the first quarter of 2015 alone - with some $508 million being in the U.S.
UPDATE 1-FDA approves generic versions of antipsychotic drug Abilify  Reuters
Game on: FDA approves first generics of blockbuster antipsychotic Abilify  BioPharma Dive
It's A Big Weekend For Biotech
Merck & Co, Inc. (NYSE: MRK) and Bristol-Myers Squibb Co (NYSE: BMY). Merck and Bristol-Myers are headlining this year's conference, and analysts are looking for data on key cancer drugs from both companies ahead of next month's American Society of ...
Bristol-Myers Squibb Co's (BMY) Opdivo Gains Positive EMA Opinion For ...
Bristol-Myers Squibb Co (NYSE:BMY)announced Friday that its advanced melanoma treatment, Opdivo, has pocketed a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), for its ...
BMS' Opdivo backed as melanoma therapy in EU  PMLiVE
Eliquis surge, Abilify's last gasp send BMS sailing to a street-beating Q1  FiercePharma